

4/13/04

PTO/SB/08a (08-03)

Approved for use through 07/31/2008, OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

**Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.**

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Application Number	10/789,354
		Filing Date	February 27, 2004
		First Named Inventor	Cirillo, P.F. et al
		Art Unit	to be assigned
		Examiner Name	to be assigned
<i>(Use as many sheets as necessary)</i>	1	of	5
Sheet	Attorney Docket Number 9/276		

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

*(Use as many sheets as necessary)*

- She

1

## U. S. PATENT DOCUMENTS

## **FOREIGN PATENT DOCUMENTS**

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)			
B		WO 01/53274	07/26/2001	Agouron Pharmaceut.	
RJ		WO 01/51456	07/19/2001	Tularik Inc.	
RJ		WO 99/51580	10/14/1999	Abbott Laboratories	
RJ		WO 99/43672	09/02/1999	Genetics Institute, Inc.	
RJ		WO 02/30894	04/18/2002	Taiho Pharmaceutical	

Examiner Signature	R. Devar	Date Considered	11/4/05
<p><b>*EXAMINER:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at <a href="http://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language translation is attached.</p>			

Translation is attached.  
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<i>Complete if Known</i>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/789,354
				Filing Date	February 27, 2004
				First Named Inventor	Cirillo, P.F. et al
				Art Unit	to be assigned
				Examiner Name	to be assigned
<i>(Use as many sheets as necessary)</i>				Attorney Docket Number	9/276
Sheet	2	of	5		

## **U. S. PATENT DOCUMENTS**

## **FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No.*	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T#
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
RS		WO 01/44445	06/21/2001	Incyte Genomics, Inc.		
RS		WO 02/24635	03/28/2002	Fujisawa Pharm. Co.		
RS		WO 02/28820	04/11/2002	Merck Patent GmbH		
RS		WO 00/26197	05/11/2000	Bristol-Myers Squibb		
RS		WO96/16954	06/06/1996	Agrevo UK		

Examiner Signature	<u>R. D. Gray</u>	Date Considered	11/4/05
-----------------------	-------------------	--------------------	---------

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if Not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 801.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

**Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.**

Substitute for form 1449A/PTO

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

*(Use as many sheets as necessary)*

Sheer

3

5

**Complete if Known**

Application Number	10/789,354
Filing Date	February 27, 2004
First Named Inventor	Cirillo, P.F. et al
Art Unit	to be assigned
Examiner Name	to be assigned
Attorney Docket Number	9/276

**U. S. PATENT DOCUMENTS**

## **FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (# Known)				
BB		WO 00/44737	08/03/2000	Eli Lilly and Company		
KC		WO 98/22452	05/28/1998	Kyowa Hakko Kogyo		
BB		WO 97/29105	08/14/1997	Kumiai Chemical Co.		
BC		WO 00/75120	12/14/2000	Agouron Pharmac. Co		
BB		WO 99/01423	01/14/1999	Novo Nordisk Ag.		

**Examiner Signature** R. DeLeon **Date Considered** 11/6/05

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		<i>Complete if Known</i>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Application Number	10/789,354
		Filing Date	February 27, 2004
		First Named Inventor	Cirillo, P.F. et al
		Art Unit	to be assigned
		Examiner Name	to be assigned
<i>(Use as many sheets as necessary)</i>		Attorney Docket Number	9/276
Sheet	4	of	5

## **U. S. PATENT DOCUMENTS**

## **FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
RJ		WO 00/06550	02/10/2000	Nippon Soda Co.		
RJ		JP 2000 256358	09/19/2000	Yamanouchi Pharm.		
RJ		WO 99/45002	09/10/1999	Kyowa Hakko Kogyo		

Examiner Signature	R. Decker	Date Considered	11/4/08
-----------------------	-----------	--------------------	---------

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. **1** Applicant's unique citation designation number (optional). **2** See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. **3** Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). **4** For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. **5** Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. **6** Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete If Known</b>	
				<i>Application Number</i>	10/789,354
				<i>Filing Date</i>	February 27, 2004
				<i>First Named Inventor</i>	Cirillo, P.F. et al
				<i>Art Unit</i>	to be assigned
				<i>Examiner Name</i>	to be assigned
Sheet	5	of	5	Attorney Docket Number	9/276


NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
R		Abstract of JP 2000/256358 Pyrazole Derivative- September 19, 2000 - Kubota, K., et al - Yamanouchi Pharmaceutical Co. Ltd.			
RE		Abstract of WO 00/06550 - Phenylazole Compounds, Process for Producing the Same and Drugs for Hyperlipemia, February 10, 2000, Kunihiro, I., et al ;			
RE		Abstract of WO 99/45002 - Benzofuran Derivatives, September 10, 1999, Ichiro, M., et al			
RE		Abstract of WO 98/22452 - Benzofuran Derivatives, May 28, 1998, Etsuo, O., et al			
RE		Abstract of WO 97/29105 - Benzofuran-7-Yluracil Derivatives and Herbicides, Masahiro, M., et al			

Examiner Signature	<i>R. Desai</i>	Date Considered	11/4/05
--------------------	-----------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.  
 This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08b (08-03)

Approved for use through 06/30/2008. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

4

## Complete if Known

Application Number	10/789,354
Filing Date	2/27/2004
First Named Inventor	Pier Francesco CIRILLO
Art Unit	1625
Examiner Name	Rita J. Desai
Attorney Docket Number	9/276

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
R		"Tumor Necrosis Factor Inhibitors"; Early Alert Report, Fall 2000	
R		van HEEL, D. A ET AL; "Inflammatory bowel disease is associated with a TNF polymorphism that affects an interaction between the OCT1 and NF-kB transcription factors"; Human Molecular Genetics (2002): 1281-1289	
R		WEBB, G. R., ET AL; "Chondrocyte tumor necrosis factor receptors and focal loss of cartilage in osteoarthritis"; Osteoarthritis and Cartilage, 1997, 5, 427-437	
R		RAINE, C. S. ET AL; "Multiple sclerosis: expression of molecules of the tumor necrosis factor ligand and receptor families in relationship to the demyelinated plaque"; Rev. Neurol. (Paris) 1998, 154, 577-585	
R		MA, J. J. ET AL; "Genetic Contribution of the Tumor Necrosis Factor Region in Guillain-Barré Syndrome"; Annals of Neurology, 1998, 44, 815-818	
R		CHODOROWSKA, C. ET AL; "Plasma concentrations of IFN-gamma and TNF-alpha in psoriatic patients before and after local treatment with dithranol ointment"; J. Eur. Acad. Dermatology And Venereology, 1998, 10, 147-151	
R		NAGLER, A. ET AL; "Dysregulation of inflammatory cytokines in unrelated bone marrow transplantation"; Cytokines, Cellular & Molecular Ther., 1998, 4, 161-167	
R		ROBAK, E., "Association of Interferon gamma, Tumor Necrosis Factor alpha and Interleukin 6 Serum Levels with Systemic Lupus Erythematosus Activity"; Archivum Immunologiae et Therapiae Experimentalis, 1998, 46, 375-380	
R		TASHIRO, H. ET AL; "Role of cytokines in the pathogenesis of restenosis after percutaneous transluminal coronary angioplasty"; Coronary Artery Disease, 12: 107-113	
R		BROWN, G. R. ET AL; "Lymphoid Hyperplasia, CD45RBhigh to CD45RBlow T-cell imbalance, and suppression of Type I diabetes mellitus result from TNF blockade in NOD-NOD-scid adoptive T cell transfer"; Diabetologia, 1998, 41, 1502-1510	

Examiner Signature	<i>Rita J. Desai</i>	Date Considered	11/4/08
--------------------	----------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.  
 This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet <b>2</b> of <b>4</b>				<b>Complete If Known</b>
Application Number	10/789,354			
Filing Date	2/27/2004			
First Named Inventor	Pier Francesco CIRILLO			
Art Unit	1625			
Examiner Name	Rita J. Desai			
	Attorney Docket Number			9/276

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
RJ		SOLTYS, J. ET AL; "Modulation of Endotoxin- and Enterotoxin-Induced Cytokine Release by In Vivo Treatment with beta-(1,6)-Branched beta-(1,3)-Glucan"; Infection and Immunity, 1999, 244-252	
RJ		BJUGSTAD, K. B. ET AL; "Preventive actions of a synthetic antioxidant in a novel animalmodel of AIDS dementia1"; Brain Research, 1998, 795, 349-357	
RJ		CHOU, R. C. ET AL; "Adrenergic regulation of macrophage-derived tumornecrosis factor-alpha generation durng a chronic polyarthritis pain model"; J. Neuroimmunol., 1998, 82, 140-148	
RJ		MUELLER, G. ET AL; "Is Cytokine Expression Responsible for Differences Between Allergens and Irritants?"; American J. of Contact Dermitis, Vol. 7, No. 3 (September), 1996, 177-184	
RJ		ELHAGE, R. ET AL; "Differential Effects of Interleukin-1 Receptor Antagonist and Tumor Necrosis Factor Binding Protein on Fatty-Streak Formation in Apolipoprotein E-Deficient Mice"; Circulation, 1998, 97:242-244	
RJ		RYFFEL, B. ET AL; "Failure to induce anti-glomerular basement membrane glomerulonephritis in TNFalpha/beta deficient mice"; Int. J. Exp. Path., 1998, 79, 453-460	
RJ		MITSUI, Y. ET AL; "The expression of proinflammatory cytokine mRNA in the sciatic-tibial nerve of ischemia-reperfusion injury"; Brain Research, 844 (1999), 192-195	
RJ		LI, D. ET AL, "Kinetics of tumor necrosis factor alpha in plasma and the cardioprotective effect of a monoclonal antibody to tumor necrosis factor alpha in acute myocardial infarction" Amer. Heart Journal, 1999, 137, 1145-1152	
RJ		YEH, F. L. ET AL, "Changes in serum tumour necrosis factor-alpha in burned patients"; Burns, 1997, 23, 6-10	
RJ		RENZETTI, L. M. ET AL; "Ro 45-2081, a TNF receptor fusion protein, prevents inflammatory responses in the airways"; Inflamm. Res. 1997, 46, Suppl. 2, S143-S144	

Examiner Signature	<i>RJDesai</i>	Date Considered	11/4/05
--------------------	----------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet <b>3</b> of <b>4</b>				<b>Complete if Known</b>
Application Number	10/789,354			
Filing Date	2/27/2004			
First Named Inventor	Pier Francesco CIRILLO			
Art Unit	1625			
Examiner Name	Rita J. Desai			
				Attorney Docket Number 9/276

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
RD		LEMAY, S. ET AL; "Prominent and Sustained Up-regulation of gp130-Signaling Cytokines and of the Chemokine MIP-2 in Murine Renal Ischemia-Reperfusion Injury"; Transplantation, Vol. 69, No. 5, (2000), 959-963			
RD		BOERJESSON, A. ET AL; "TNF-alpha stimulates alveolar liquid clearance during intestinal ischemia-reperfusion in rats"; Am. J. Physiol. Lung Cell. Mol. Physiol., (2000) 278:L3-L12			
RD		KUROKOUCHI, K. ET AL; "TNF-alpha Increases Expression of IL-6 and ICAM-1 Genes Through Activation of NFkB in Osteoblast-like ROS17/2.8 Cells"; J. Bone and Mineral Res., 1998, 13, 1290-1299			
RD		HIGHAM, M. A. ET AL; "Tumour necrosis factor-alpha gene promoter polymorphism in chronic obstructive pulmonary disease"; Eur. Respir J. 2000, 15:281-284			
RD		TAKABATAKE, N. ET AL; "The Relationship between Chronic Hypoxemia and Activation of the Tumor Necrosis Factor-alpha System in Patients with Chronic Obstructive Pulmonary Disease"; Am. J. Respir. Crit. Care Med., Vol. 161, 2000, 1179-1184			
RD		LEE, T. H.; "Cytokine networks in the pathogenesis of bronchial asthma: implications for therapy"; J. of the Royal Coll. of Phys. of London, Vol. 32, No. 1, Jan/Feb. 1998; 56-64			
RD		LIPTON, J. M. ET AL; "Peptide Modulation of Inflammatory Processes within the Brain"; Neuroimmunomodulation, 1998, 5, 178-183			
RD		BRANGER, J. ET AL; "Anti-Inflammatory Effects of a p38 Mitogen-Activated Protein Kinase Inhibitor During Human Endotoxemia"; J. Immunol. 2002, 168: 4070-4077			
RD		VISCARDI, R. M. ET AL; "Inflammatory Cytokine mRNAs in Surgical Specimens of Necrotizing Enterocolitis and Normal Newborn Intestine"; Pediatric Pathol. And Lab. medicine, 1997, 17, 547-559			
RD		PARIS, M. M. ET AL; "The Effect of Interleukin-10 on Meningeal Inflammation in Experimental Bacterial Meningitis"; J. Infectious Dis. 1997, 176, 1239-1246			

Examiner Signature	<i>R. Desai</i>	Date Considered	11/4/05
--------------------	-----------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.**

Substitute for form 1449B/PTO				<i>Complete If Known</i>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<i>Application Number</i>	10/789,354
				<i>Filing Date</i>	2/27/2004
				<i>First Named Inventor</i>	Pier Francesco CIRILLO
				<i>Art Unit</i>	1625
				<i>Examiner Name</i>	Rita J. Desai
<i>(Use as many sheets as necessary)</i>				<i>Attorney Docket Number</i>	9/276
Sheet	4	of	4		

## **NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		BAHRAMI, S. ET AL; "Significance of TNF in hemorrhage-related hemodynamic alterations, organ injury, and mortality in rats"; Am. J. Physiol. 1997, 272 (Heart Circ. Physiol. 41) H2219	
		AMEGLIO, F. ET AL; "Bullous pemphigoid and pemphigus vulgaris: correlated behaviour of serum VEGF, sE-selectin and TNF-alpha levels"; J. Biol. Regul. Homeost. Agents, 1997, 11, 148	

Examiner Signature	R. Desai	Date Considered	1/14/05
--------------------	----------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.**

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.